GLP-1 Drugs and Kidney Disease - Who Benefits Most and What Comes Next

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to basket failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Adding to library failed

Please try again

Follow podcast failed

Unfollow podcast failed

GLP-1 Drugs and Kidney Disease - Who Benefits Most and What Comes Next

Listen for free

View show details

About this listen

Join host Julia Cartwright as she explores who benefits most from GLP-1 receptor agonists in kidney disease treatment. From the groundbreaking FLOW trial results in diabetic patients to emerging research in non-diabetic kidney disease, discover what four pillars of modern kidney care mean for patients facing declining function, and what cutting-edge biopsy studies reveal about these medications' future potential.

Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

This content was created in partnership and with the help of Artificial Intelligence AI

No reviews yet